Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In re: GERON CORPORATION SECURITIES LITIGATION
Case Number:
3:14-cv-01224
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
March 03, 2017
Geron, Investors Reach $6.25M Settlement In Cancer Drug Suit
A proposed class of Geron Corp. investors have sought approval in California federal court for a $6.25 million settlement regarding claims that the company improperly touted a cancer drug before the U.S. Food and Drug Administration halted a clinical trial over liver toxicity concerns.
-
April 10, 2015
Geron Gets Shareholder Action Over Cancer Drug Trimmed
A California federal judge on Friday trimmed a consolidated proposed shareholder class action accusing Geron Corp. of improperly touting the prospects of its cancer drug imetelstat before the U.S. Food and Drug Administration put a hold on the drug's clinical trial over concerns of liver toxicity.
-
March 19, 2014
Geron Faces Investor Suit After FDA Halts Clinical Trial
Geron Corp. was hit with a shareholder class action Friday in California federal court accusing the drugmaker of improperly touting the prospects of its sole drug candidate before the U.S. Food and Drug Administration put a hold on the drug's clinical trial over concerns of liver toxicity.